The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Sullivan Timothy Eugene since 2019.
This trader's CIK number is 1707000.
At the time of last reporting, Sullivan Timothy Eugene was the Chief Financial Officer of Apellis Pharmaceuticals, Inc.. (stock ticker symbol APLS).
Also see all insider trading activities at Apellis Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | APLS | 0 | $0 | 7,534 | $224,185 | 0 | $0 |
| 2024 | APLS | 0 | $0 | 12,123 | $769,841 | 4,000 | $40,120 |
| 2023 | APLS | 0 | $0 | 90,716 | $7,607,985 | 90,716 | $909,880 |
| 2021 | APLS | 0 | $0 | 0 | $0 | 39,880 | $399,996 |
| 2019 | APLS | 11,699 | $347,635 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-01-29 | APLS | Sale | 546 | 29.52 | 16,120 |
| 2025-01-22 | APLS | Sale | 3,088 | 30.43 | 93,955 |
| 2025-01-17 | APLS | Sale | 1,730 | 29.96 | 51,827 |
| 2025-01-13 | APLS | Sale | 2,170 | 28.70 | 62,283 |
| 2024-04-01 | APLS | Option Ex | 4,000 | 10.03 | 40,120 |
| 2024-04-01 | APLS | Sale | 4,000 | 58.66 | 234,640 |
| 2024-02-12 | APLS | Sale | 1,431 | 67.77 | 96,974 |
| 2024-01-29 | APLS | Sale | 906 | 64.14 | 58,109 |
| 2024-01-22 | APLS | Sale | 3,551 | 65.00 | 230,800 |
| 2024-01-16 | APLS | Sale | 2,235 | 66.81 | 149,318 |
| 2023-11-30 | APLS | Sale | 14,158 | 54.76 | 775,263 |
| 2023-11-30 | APLS | Option Ex | 14,158 | 10.03 | 142,004 |
| 2023-07-03 | APLS | Sale | 6,779 | 90.31 | 612,204 |
| 2023-07-03 | APLS | Option Ex | 6,779 | 10.03 | 67,993 |
| 2023-06-05 | APLS | Option Ex | 69,779 | 10.03 | 699,883 |
| 2023-06-05 | APLS | Sale | 69,779 | 89.15 | 6,220,518 |
| 2021-06-08 | APLS | Option Ex | 39,880 | 10.03 | 399,996 |
| 2019-08-29 | APLS | Buy | 11,699 | 29.71 | 347,635 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sullivan Timothy Eugene (Chief Financial Officer of Apellis Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.